The treatment of hypertension in pregnancy
M. Peter Moore, Christopher W.G. Redman
Abstract
M. Peter Moore, Christopher W.G. Redman
Abstract
SummaryThe rationale for the drug treatment of severe maternal hypertension occurring concurrently with or induced by pregnancy is discussed. Methyldopa is the antihypertensive agent most commonly used at present in pregnancy but recently the use of beta-blocking drugs and the combined alpha-blocker and beta-blocker labetalol has been advocated. Interim results from 74 patients in an ongoing randomized trial comparing methyldopa (1. 0 to 4.0 g/day) with labetalol (0.3 to 1.2 g/day) indicate that the two drugs have an equivalent antihypertensive effect and both cause side-effects. There is no evidence that either drug significantly altered the progression of established pre-eclampsia.
OpenAlex reports 20 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
SummaryThe rationale for the drug treatment of severe maternal hypertension occurring concurrently with or induced by pregnancy is discussed. Methyldopa is the antihypertensive agent most commonly used at present in pregnancy but recently the use of beta-blocking drugs and the combined alpha-blocker and beta-blocker labetalol has been advocated. Interim results from 74 patients in an ongoing randomized trial comparing methyldopa (1. 0 to 4.0 g/day) with labetalol (0.3 to 1.2 g/day) indicate that the two drugs have an equivalent antihypertensive effect and both cause side-effects. There is no evidence that either drug significantly altered the progression of established pre-eclampsia.
Key concepts: Labetalol, Medicine, Methyldopa, Pregnancy, Hypertension in Pregnancy, Eclampsia, Drug, Randomized controlled trial